We noticed you’re blocking ads

Thanks for visiting MillennialEYE. Our advertisers are important supporters of this site, and content cannot be accessed if ad-blocking software is activated.

In order to avoid adverse performance issues with this site, please white list https://millennialeye.com in your ad blocker then refresh this page.

Need help? Click here for instructions.

In Your Head | Sept/Oct '17

In Your Head: ESCRS Wish List

Mitchell A. Jackson, MD

Trifocal IOL technology, including the AT LISA (Carl Zeiss Meditec), Lentis Mplus (Oculentis), and FineVision (PhysIOL). All three lenses provide a vast array of advantages for various patient needs. The AT LISA favors distance and near and may be problematic for intermediate, but it does come in a toric version if needed. The Lentis Mplus is a segmented bifocal lens and can be oriented in any direction, unlike bifocal glasses, but corneal aberrations must be minimal; this IOL is available in a toric version and has minimal night glare and halo issues. The FineVision lens is a diffractive IOL that provides good intermediate vision, but it may have typical glare and halo issues seen with current FDA-approved multifocal IOLs.

Karolinne Rocha, MD, PhD

Pinhole IOLs—this technology provides patients with an extended depth focus and is a great option for highly aberrated eyes.

Gregory Parkhurst, MD

The EVO Visian ICL and EVO Visian toric ICL (both STAAR Surgical) have a central fenestration, obviating the need for peripheral iridotomy. This makes phakic IOL surgery even easier on the patient, as it eliminates the need for another procedure. The fenestration in the ICL also eliminates the risk of pupil block and allows aqueous humor flow to bathe the anterior lens epithelial cells, decreasing the risk of cataract to even lower levels than we already see. This is a great minor modification to an already-approved and awesome product. I’m excited for the day when my patients in the United States have access to this simple but important device modification.

NEXT IN THIS ISSUE